Trial · NCT06882785
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
NCT06882785, Phase 3, Recruiting, Bristol-Myers Squibb
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia. Trials, record NCT06882785. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06882785
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
- NCT number
- NCT06882785
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 250 participants, estimated
- Lead sponsor
- Bristol-Myers Squibb
- Conditions
- Schizophrenia
- Interventions
- KarXT, Placebo
- First posted
- 2025-03-19
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes35
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score | At week 5 | Double-Blind Part |
| Primary | Number of participants with treatment-emergent adverse events (TEAEs) | At Week 52 from OLE baseline | Open-label extension (OLE) Part |
| Secondary | Change from baseline in PANSS positive score | At week 5 | Double-blind Part |
| Secondary | Change from baseline in PANSS negative score | At week 5 | Double-blind Part |
| Secondary | Change from baseline in PANSS Negative Marder Factor score | At week 5 | Double-blind Part |
| Secondary | Change from baseline in Clinical Global Impressions-Severity (CGI-S) score | At week 5 | Double-blind Part |
| Secondary | The percentage of PANSS responders (a ≥ 30% change in PANSS total score) | At week 5 | Double-blind Part |
| Secondary | Number of participants wtih adverse events (AEs) | Up to day 35 | Double-blind Part |
| Secondary | Number of participants wtih adverse events of special interest (AESIs) | Up to week 57 | |
| Secondary | Number of participants with procholinergic symptoms | Up to week 57 |
1 to 10 of 35Source ClinicalTrials.gov
See all 35 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06882785
GET https://conductscience.org/api/trials/v1/NCT06882785/registered?page=2